ATRX and primitive neuroectodermal tumor: Five-year disease-free survival dropped from around 96% in ATRX/DAXX-intact cases to around 40% in ATRX/DAXX-deficient cases.112 Similarly, higher Ki-67 proliferation rate correlated with early recurrence.113 These molecular markers thus identify high-risk PNET subtypes warranting closer surveillance and adjuvant strategies.